ALDERIA INTELLIGENCE

All Signals

120 signals from cardiometabolic research

120 of 120 signals

ClinicalTrials20 Apr 2026·Phase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease

Phase 3 cardiovascular and kidney outcomes trial testing retatrutide in adults with BMI ≥27 kg/m² and atherosclerotic cardiovascular disease and/or chronic kidney disease. Enrollment targets 10,000 participants in a double-blind, placebo-controlled, event-driven design running approximately 5 years through February 2029. Eli Lilly advances retatrutide into major outcomes territory, competing directly with established GLP-1 agents that already hold cardiovascular indications like Wegovy and future tirzepatide expansions. This represents the largest cardiovascular outcomes program for any triple agonist to date.

CardiovascularKidneyWeight lossEli Lilly
ClinicalTrials20 Apr 2026·Phase 3

A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial

Phase 3b trial evaluating different retatrutide dose escalation strategies in adults with obesity or overweight without type 2 diabetes. Target enrollment is 600 participants with approximately 113 weeks study duration in a randomized, double-blind, controlled design. Eli Lilly is testing optimization of their triple agonist dosing in the weight management indication, building on tirzepatide's success in the same population. This represents systematic dose-finding work for retatrutide ahead of potential regulatory filings.

GLP-1Weight lossEli Lilly
ClinicalTrials20 Apr 2026·Phase 3

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Phase 3 trial testing orforglipron versus placebo in people with obesity or overweight, with and without type 2 diabetes, measuring HbA1c change as primary endpoint. Enrolling 600 participants with 18-month study duration, part of larger master protocol study. Eli Lilly advances the first approved small-molecule oral GLP-1 into obesity indication, expanding beyond its April 2026 type 2 diabetes approval. This represents a direct challenge to Novo Nordisk's oral semaglutide, which gained FDA approval for obesity in January 2026.

GLP-1Weight lossType 2 diabetesEli Lilly
PubMed19 Apr 2026·Obesity (Silver Spring, Md.)● 6/10i

Prevalence of Preclinical and Clinical Obesity Among US Children and Adolescents Aged 5 to 18 Years: NHANES 2017-2023.

One in five US youth aged 5-18 have obesity using the new Lancet Diabetes & Endocrinology Commission framework, with 12.5% having clinical obesity that includes physiological dysfunction. Cross-sectional analysis of NHANES 2017-2023 data from 5,513 youth, comparing traditional BMI percentile classification with the new framework that incorporates waist-to-height ratio and clinical impairments. This provides the first US population-level data applying the new obesity framework that shifts focus from BMI alone to physiological dysfunction, potentially expanding the pediatric population eligible for medical intervention. The analysis reveals limitations in routinely collected clinical data for implementing the new classification system in practice.

Weight lossReal-world evidence
ClinicalTrials17 Apr 2026·Phase 3● 8/10iHigh impactPick of the week

The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis

Phase 3 trial evaluates semaglutide versus placebo in adults with non-cirrhotic NASH, measuring steatohepatitis resolution, fibrosis improvement, and cirrhosis-free survival over approximately 5 years. The study enrolled 1,205 adults and is active but not recruiting, with completion expected in 2029. This represents Novo Nordisk's push into NASH, a major unmet need with no approved GLP-1 therapies despite strong preclinical rationale. The trial's dual primary endpoints and 5-year duration suggest preparation for a pivotal regulatory filing in this large addressable market.

GLP-1Liver/NASHNovo Nordisk
ClinicalTrials17 Apr 2026·Phase 3● 8/10iHigh impact

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Phase 3 trial evaluating retatrutide for chronic low back pain in people with obesity or overweight, targeting dual primary endpoints of pain intensity reduction and weight loss. 586-person placebo-controlled study expected to complete September 2027, investigating a novel indication beyond traditional metabolic endpoints. Eli Lilly is exploring pain management as a potential expansion for their triple agonist, representing the first major trial of a GLP-1-based therapy specifically for chronic pain conditions.

GLP-1Weight lossOtherEli Lilly
ClinicalTrials17 Apr 2026·Phase 3● 8/10iHigh impact

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease

Phase 3 cardiovascular outcomes trial testing orforglipron versus placebo in people with established atherosclerotic cardiovascular disease and/or chronic kidney disease. Event-driven study enrolling 7,140 participants with expected completion in August 2031, approximately 5 years duration. This positions Eli Lilly to compete directly with Novo Nordisk's cardiovascular claims for semaglutide by establishing orforglipron as the first small-molecule oral GLP-1 with proven cardiovascular benefits. The trial targets a high-risk population already established for GLP-1 cardiovascular benefit validation.

GLP-1CardiovascularEli Lilly
ClinicalTrials17 Apr 2026·Phase 3● 8/10iHigh impact

A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Phase 3 open-label trial compared once-daily oral orforglipron versus insulin glargine in people with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study enrolled 2,749 participants with primary endpoint of time to first major adverse cardiovascular event, completed in March 2026. Eli Lilly is positioning orforglipron as a cardiovascular outcomes option in high-risk populations, directly competing with established insulin therapy in this indication. This represents the first cardiovascular outcomes trial for orforglipron following its April 2026 FDA approval for type 2 diabetes.

GLP-1Type 2 diabetesWeight lossCardiovascularEli Lilly
ClinicalTrials17 Apr 2026·Phase 3● 7/10i

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes

Phase 3 randomized placebo-controlled trial testing once-weekly eloralintide in adults with persistent obesity or overweight on stable incretin therapy, with or without type 2 diabetes. Enrolling 900 participants over 80 weeks, targeting percent change in body weight from baseline. Eli Lilly is exploring combination therapy for people who have insufficient weight loss on existing GLP-1 agents, addressing a growing clinical need as incretin adoption expands. The add-on approach represents a different strategy from Novo Nordisk's CagriSema fixed-dose combination currently in Phase 3.

GLP-1Weight lossDrug comparisonsEli Lilly
PubMed17 Apr 2026·Diabetes, obesity & metabolism● 7/10i

Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study.

GLP-1 receptor agonists reduced Parkinson's disease risk by 19% versus sulfonylureas in adults with type 2 diabetes, with incidence rates of 5.2 versus 8.0 per 10,000 person-years. Scandinavian cohort study of 347,026 new users across three countries, with liraglutide accounting for 73% of GLP-1 exposure followed by semaglutide at 13%. This provides the first large-scale evidence for neuroprotective effects beyond weight loss and glycemic control in the GLP-1 class. The observational design cannot establish causation, requiring validation in randomized trials.

GLP-1Brain/NeuroType 2 diabetesNovo NordiskEli Lilly
PubMed17 Apr 2026·Annals of internal medicine● 7/10i

Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review.

Incretin-based therapies caused muscle-related losses that exceeded expected benchmarks in two-thirds of studies, with a median 34.9% of total weight loss coming from muscle-based tissue rather than the expected 25% threshold. Systematic review of 36 randomized controlled trials with median 71 participants and 26-week duration across liraglutide, semaglutide, tirzepatide, and dulaglutide. This quantifies a clinically important side effect profile that has received limited systematic evaluation despite widespread prescribing of these agents for weight management. The analysis was limited by heterogeneous measurement methods that prevented meta-analysis.

Weight lossGLP-1Side effectsNovo NordiskEli Lilly
PubMed17 Apr 2026·Diabetes, obesity & metabolism● 6/10i

Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials.

Semaglutide demonstrated enhanced HbA1c and weight reduction in adults with type 2 diabetes aged ≤40 years compared to older age groups across the SUSTAIN and PIONEER programs. Post hoc analysis of pooled phase 3 trials comparing subcutaneous and oral semaglutide against placebo and active comparators across age subgroups. This provides the first dedicated efficacy analysis of GLP-1 therapy in young adults with type 2 diabetes, supporting earlier intervention strategies. Safety profiles remained comparable across all age groups.

GLP-1Type 2 diabetesNovo Nordisk
PubMed17 Apr 2026·Current obesity reports● 5/10i

Metabolic Dysfunction-Associated Steatotic Liver Disease and Respiratory Disorders: A Systematic Review of Clinical and Pathophysiological Associations.

MASLD prevalence was high among people with COPD and obstructive sleep apnea, and was associated with worse respiratory phenotypes, increased exacerbations, and higher respiratory mortality. Systematic review of 22 studies (21 observational, 1 Mendelian randomization) examining MASLD-respiratory disease associations. This establishes MASLD as a marker of systemic metabolic dysfunction that extends beyond liver disease, potentially expanding the addressable patient population for metabolic therapies targeting liver-lung axis crosstalk. Mendelian randomization studies did not consistently support causal relationships except for OSA.

Weight lossLiver/NASHOtherEli Lilly
PubMed17 Apr 2026·Circulation. Population health and outcomes● 4/10i

Leveraging Neighborhood-Level Interventions to Improve Cardiovascular Health: A Scoping Review.

Neighborhood-level interventions improved cardiovascular health behaviors in 55% of studies, with dietary outcomes showing greatest benefit at 73% and physical activity at 63%. Scoping review of 20 studies including 15 RCTs and 5 quasi-experimental studies targeting built environments, food access, and housing mobility. This provides the first systematic evidence that environmental modifications combined with community support can address social determinants of cardiovascular disease at population scale. However, interventions showed limited impact on clinical cardiometabolic risk factors, suggesting behavioral changes may not translate to measurable health outcomes.

CardiovascularReal-world evidence
PubMed17 Apr 2026·Diabetes, obesity & metabolism● 4/10i

Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.

Orforglipron tablets and capsules demonstrated pharmacokinetic bioequivalence across six dose levels in 429 healthy adults with obesity or overweight. Phase 1, multicenter, open-label study with multiple-dose escalation over 7 days at each dose strength. This establishes formulation flexibility for Eli Lilly's newly approved small-molecule oral GLP-1, potentially supporting manufacturing scale-up and future dose optimization strategies. Safety profiles were similar between formulations with mostly mild adverse events.

GLP-1Type 2 diabetesEli Lilly
ClinicalTrials16 Apr 2026·Phase 3● 8/10iHigh impact

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Phase 3 master protocol testing oral orforglipron versus placebo in adults with obesity or overweight, with or without type 2 diabetes. Enrolling 1,200 participants across two sub-studies, expected completion August 2027, placebo-controlled design. Eli Lilly advances orforglipron into obesity treatment following its April 2026 FDA approval for type 2 diabetes, representing the first small-molecule oral GLP-1 to enter weight management. This positions Eli Lilly to challenge Novo Nordisk's dominance in oral GLP-1 obesity treatment, where oral semaglutide gained approval in January 2026.

GLP-1Weight lossType 2 diabetesEli LillyNovo Nordisk
ClinicalTrials16 Apr 2026·Phase 3● 7/10i

A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase III Trial Evaluating Long-term Efficacy and Safety of Survodutide Weekly Injections in Adult Participants With Noncirrhotic Non-alcoholic Steatohepatitis/Metabolic Dysfunction-associated Steatohepatitis (NASH/MASH) and (F2) - (F3) Stage of Liver Fibrosis

Boehringer Ingelheim is testing survodutide, a weekly injectable, versus placebo in 1,800 adults with MASH and moderate to advanced liver fibrosis (F2-F3). This placebo-controlled trial runs up to 7 years with dual primary endpoints: MASH resolution without fibrosis worsening and composite clinical outcomes including progression to cirrhosis. This positions Boehringer as the first major pharma to advance a dedicated MASH program into Phase 3, targeting a liver indication where Novo's semaglutide and Eli Lilly's tirzepatide have shown promise but lack specific approvals. The 7-year duration reflects the extended timeline needed to demonstrate meaningful liver outcomes in this progressive disease.

Liver/NASHGLP-1Boehringer Ingelheim
ClinicalTrials16 Apr 2026·Phase 3● 7/10i

A Phase III Double-blind, Randomised, Placebo-controlled Trial to Evaluate Liver-related Clinical Outcomes and Safety of Once Weekly Injected Survodutide in Participants With Compensated Non-alcoholic Steatohepatitis/Metabolic Dysfunction Associated Steatohepatitis (NASH/MASH) Cirrhosis

Boehringer Ingelheim is testing survodutide, a once-weekly injectable, in people with compensated NASH/MASH cirrhosis in a phase 3 trial targeting liver-related clinical outcomes. The randomized, placebo-controlled study aims to enroll 1,590 participants over 4.5 years, measuring time to death, liver transplant, hepatic decompensation, or disease progression. This represents Boehringer's entry into the competitive NASH space where Novo Nordisk's semaglutide is already in phase 3 trials for non-cirrhotic NASH. The trial focuses on advanced cirrhotic patients, a population with high unmet need but challenging regulatory pathway.

Liver/NASHGLP-1Boehringer IngelheimNovo Nordisk
ClinicalTrials16 Apr 2026·Phase 3● 7/10i

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Orforglipron, Eli Lilly's oral small-molecule GLP-1 receptor agonist, is being tested against placebo for weight management in people with obesity or overweight without type 2 diabetes. The phase 3 trial targets 600 participants over 18 months, measuring percent change in body weight as the primary endpoint. This represents Eli Lilly's push to expand orforglipron beyond its April 2026 FDA approval for type 2 diabetes into the weight management market, competing directly with Novo Nordisk's approved oral semaglutide for obesity. The trial is part of a broader master protocol evaluating orforglipron across multiple obesity-related populations.

GLP-1Weight lossEli Lilly
PubMed16 Apr 2026·European heart journal● 7/10i

PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study.

PCSK9 inhibitor monoclonal antibodies reduced major cardiovascular events by 31% versus standard care in people with atherosclerotic cardiovascular disease but without prior ischemic events. Real-world observational study using US claims data, 19,670 patients followed for 5 years with propensity score matching. This provides the first large-scale real-world evidence for PCSK9 inhibitors in primary prevention within high-risk ASCVD populations, extending beyond the clinical trial evidence that has driven current guidelines. The observational design limits causal inference compared to randomized controlled trials.

PCSK9CardiovascularReal-world evidenceAmgenRegeneron
PubMed16 Apr 2026·Diabetes, obesity & metabolism● 7/10i

Cardiometabolic Profiles of Oral and Subcutaneous Glucagon-Like Peptide-1 Receptor Mono-Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta-Analysis.

Semaglutide 7.2 mg achieved the highest cardiometabolic efficacy index (0.86), followed by orforglipron 36 mg (0.68) and semaglutide 2.4 mg (0.66), all producing placebo-adjusted weight reductions ≥10%. Network meta-analysis of 19 RCTs with 13,117 adults with overweight or obesity, evaluating composite outcomes across seven cardiometabolic parameters. This provides the first head-to-head comparison of oral orforglipron against both approved and investigational semaglutide doses across multiple cardiometabolic endpoints, with orforglipron showing competitive performance despite being the first small-molecule oral GLP-1.

GLP-1Weight lossDrug comparisonsEli LillyNovo Nordisk
PubMed16 Apr 2026·BMJ open● 6/10i

Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU).

DAPA-ICU will test dapagliflozin versus placebo for one year in 600 adults at high cardiorenal risk following ICU discharge, targeting a composite of death, heart failure hospitalization, and renal decline. Multicentre, double-blind RCT across 16 French ICUs enrolling mechanically ventilated patients with elevated cardiac or renal biomarkers. This represents the first trial extending SGLT2 inhibitor cardiorenal protection to critically ill survivors, a population with 22% one-year mortality. Single-country study limits global generalizability.

SGLT2CardiovascularKidneyAstraZeneca
PubMed16 Apr 2026·BMJ open● 3/10i

Comparison of the effects of eHealth-delivered sedentary breaks versus physical activity promotion interventions on sedentary time: protocol for a systematic review and meta-analysis.

A systematic review protocol will compare eHealth-delivered sedentary break interventions versus physical activity promotion for reducing sitting time in adults. The protocol follows PRISMA-P guidelines and will search four databases through July 2025 for randomized controlled trials. This addresses a key evidence gap between two dominant digital health strategies for reducing sedentary behavior, with WHO guidelines emphasizing both increased activity and reduced sitting time. The review will include subgroup analyses by intervention duration, delivery platform, and behavioral change techniques.

Other
PubMed15 Apr 2026·Circulation research● 6/10i

Reversible Fibroblast Trajectories Regulated by MR Underlie Diastolic Dysfunction.

Mineralocorticoid receptor (MR) activation in cardiac fibroblasts drives diastolic dysfunction in heart failure with preserved ejection fraction (HFpEF) through a distinct fibroblast subtype different from myofibroblasts in heart failure with reduced ejection fraction. Preclinical study in male and female mice using aldosterone/high-salt diet and high-fat diet models, with single-nucleus RNA sequencing and fibroblast-specific MR deletion experiments. This provides the first mechanistic evidence that MR antagonists' clinical benefits in HFpEF operate through fibroblast-specific pathways rather than cardiomyocyte effects. The reversible nature of aldosterone-induced changes suggests potential for disease modification with MR antagonist therapy.

Cardiovascular
PubMed15 Apr 2026·Diabetes, obesity & metabolism● 5/10i

GLP-1, GIP, and Glucagon Excursions During a Mixed Meal Tolerance Test in Young and Lean South Asians Versus Europids.

South Asian adults showed biphasic glucose response to meals versus monophasic response in European adults, with sex-specific differences in GLP-1, GIP, and glucagon patterns despite similar BMI. Mixed meal tolerance test in 49 young, lean adults (24 South Asian, 25 European) over 240 minutes. This represents first detailed comparison of incretin hormone responses between these populations, revealing distinct metabolic phenotypes that could affect GLP-1 therapy responses. The findings suggest South Asians may need different dosing strategies or combination approaches for optimal glycemic control.

GLP-1Type 2 diabetesMechanismsEli Lilly
PubMed15 Apr 2026·Obesity research & clinical practice● 4/10i

Financial incentives for weight management in adolescents and young adults: A systematic review and meta-analysis of randomized controlled trials.

Financial incentives showed no statistically significant effects on weight loss, BMI, or blood pressure in young people with obesity across three randomized controlled trials. Meta-analysis of 408 participants with high heterogeneity (I² > 84%) and low to very low certainty evidence. This challenges assumptions about behavioral economics approaches in youth obesity interventions, where pharmaceutical companies are increasingly investing in digital health platforms and value-based care models. The small evidence base limits definitive conclusions about effectiveness.

Weight lossOther
PubMed15 Apr 2026·BMJ open● 3/10i

mHealth-based Healthy Lifestyle Promotion (MYLIFE) for metabolic syndrome risk reduction in Chinese employed adults: protocol for a cluster-randomised controlled trial.

A cluster RCT will test smartphone-based lifestyle interventions with and without wearable device add-ons for metabolic syndrome risk reduction in Chinese employed adults. Three-arm trial across 120 workplaces, 348 participants, 12-week intervention with 1-year follow-up. This represents early-stage evidence generation for workplace-based digital health solutions targeting metabolic syndrome, addressing a gap in cost-effective intervention strategies for employed populations. The study is protocol-only with no results yet available.

Other
PubMed14 Apr 2026·Circulation● 7/10iPick of the week

Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation.

GLP-1 receptor agonists reduced heart failure hospitalization risk by 23% versus DPP-4 inhibitors (HR 0.77) but matched SGLT-2 inhibitors (HR 1.02) in adults with type 2 diabetes. Target trial emulation of Swedish health records, 63,083 patients across two comparisons, 3-year follow-up. This provides the first direct head-to-head comparison of GLP-1RAs versus SGLT-2 inhibitors for heart failure prevention, confirming cardiovascular benefits extend beyond major adverse events to heart failure hospitalization.

GLP-1SGLT2Type 2 diabetesCardiovascularReal-world evidenceNovo NordiskEli Lilly
ClinicalTrials14 Apr 2026·Phase 3● 7/10i

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes

RO7795068, a dual GLP-1/GIP receptor agonist from Roche, is being tested versus placebo for weight management in people with obesity or overweight and type 2 diabetes. Phase 3 trial targets 1,600 participants over 72 weeks in a randomized, double-blind, placebo-controlled design. This positions Roche to compete directly with Eli Lilly's tirzepatide (Mounjaro/Zepbound) in the dual incretin mechanism space across both diabetes and obesity indications. The trial represents Roche's first major entry into the competitive GLP-1 obesity market dominated by Novo Nordisk and Eli Lilly.

GLP-1Weight lossType 2 diabetesDrug comparisonsHoffmann-La RocheEli Lilly
PubMed14 Apr 2026·Diabetes, obesity & metabolism● 6/10i

Discontinuation of SGLT2i After a Urogenital Infection: A Population-Based Matched Cohort Study of Patients With Type 2 Diabetes.

Patients with type 2 diabetes who experienced urogenital infections after starting SGLT2 inhibitors showed discontinuation rates of 39.5% for UTIs and 43.6% for genital infections at one year, versus 28.6% and 30.3% respectively in matched controls. Population-based matched cohort study of 68,277 SGLT2i initiators in Denmark, 2016-2021. This quantifies for the first time the medication adherence impact of SGLT2i-associated infections, despite guidelines recommending continuation through these episodes. The excess discontinuation represents approximately 8% additional treatment cessation for UTIs beyond baseline rates.

SGLT2Side effectsReal-world evidence
EMA14 Apr 2026·EC Decision — New Marketing Authorisation● 6/10i

EMA: EC Decision — New Marketing Authorisation — Pavblu (aflibercept)

The European Commission approved aflibercept (Pavblu, Amgen) for neovascular age-related macular degeneration, visual impairment from retinal vein occlusion, diabetic macular edema, and myopic choroidal neovascularization on April 14, 2026. This represents a new marketing authorization following CHMP positive opinion in January 2025. The approval establishes Amgen's entry into the competitive anti-VEGF ophthalmology market, challenging established players Regeneron/Bayer (Eylea) and Roche (Lucentis/Vabysmo) across multiple retinal indications.

OtherAmgenRegeneronBayerRoche
PubMed14 Apr 2026·Current obesity reports● 6/10i

Prevalence and Predictors of Guideline Concordant Pediatric Obesity Care: A Narrative Review.

Pharmacotherapy use remains below 2% among eligible adolescents with obesity despite 2023 American Academy of Pediatrics guidelines recommending intensive treatment including medications. Narrative review examining adoption of 13 Key Action Statements from the AAP Clinical Practice Guideline across screening, diagnosis, and treatment domains. This reveals a massive treatment gap in pediatric obesity pharmacotherapy, where established medications like semaglutide and liraglutide have pediatric approvals but face systemic barriers to implementation. Provider hesitancy, resource limitations, and insurance coverage gaps drive the underutilization.

Weight lossReal-world evidenceNovo Nordisk
PubMed14 Apr 2026·Cell metabolism● 6/10i

The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors.

Semaglutide improved liver fibrosis, steatosis, and inflammation in mice with MASH through weight-loss-independent mechanisms targeting GLP-1 receptors on liver sinusoidal endothelial cells. Preclinical study using genetically modified mouse models with targeted GLP-1 receptor deletions and transcriptomic profiling. This identifies a novel hepatic mechanism for GLP-1 receptor agonists that could support liver indication development beyond weight loss effects. Study limited to mouse models without human validation.

GLP-1Liver/NASHMechanismsNovo Nordisk
PubMed14 Apr 2026·Annals of internal medicine● 5/10i

Endocrinology: What You May Have Missed in 2025.

A review of 9 key endocrinology studies from 2025 examined treatment intensification strategies, emerging side effects of GLP-1 receptor agonists, and comparative safety data across diabetes and obesity therapies. Narrative review synthesizing published research from multiple clinical trials and observational studies. The compilation provides the first comprehensive assessment of GLP-1RA side effect concerns including nonarteritic anterior ischemic optic neuropathy alongside head-to-head comparisons of dulaglutide dose escalation versus tirzepatide switching. Limited by being a narrative review rather than systematic analysis of primary endpoints.

GLP-1SGLT2Type 2 diabetesSide effectsDrug comparisonsEli LillyNovo Nordisk
PubMed14 Apr 2026·Diabetes care● 5/10i

Seasonal BMI Amplitude and Risk of Kidney Function Decline in Japanese Adults With Type 2 Diabetes (JDDM 82).

Larger seasonal BMI fluctuations increased kidney function decline risk by 23% per standard deviation and 72% for highest versus lowest tertile in adults with type 2 diabetes. Japanese cohort study of 6,700 outpatients followed for median 6.8 years, analyzing monthly BMI patterns against multiple kidney outcomes. This establishes weight variability as an independent kidney risk factor beyond absolute weight, providing a novel screening parameter for identifying high-risk patients. Single-country data limits global generalizability.

Weight lossType 2 diabetesKidney
PubMed14 Apr 2026·Diabetes, obesity & metabolism● 4/10i

OGT Ameliorates Diabetes-Associated Cognitive Decline via Modulation of DRP1 Function and Mitochondrial Homeostasis.

OGT deficiency disrupts mitochondrial function and drives diabetes-associated cognitive decline, while semaglutide treatment for 16 weeks reversed cognitive impairment through OGT/DRP1 pathway modulation in diabetic mouse models. Preclinical study using db/db and STZ-treated mice with behavioral assessments and hippocampal gene overexpression. This provides the first mechanistic link between OGT-mediated mitochondrial homeostasis and diabetes-related brain complications, supporting a potential neuroprotective indication for GLP-1 receptor agonists.

GLP-1Type 2 diabetesBrain/NeuroMechanismsNovo Nordisk
PubMed14 Apr 2026·Annals of internal medicine● 4/10i

Gastroenterology/Hepatology: What You May Have Missed in 2025.

Nine gastroenterology and hepatology studies from 2025 showed treatment advances including new drug options for metabolic dysfunction-associated steatohepatitis and evidence that fecal microbiota transplantation matches vancomycin efficacy for first-episode C. difficile infection. Annual review of selected studies from major journals, details on study designs not specified in this overview. This compilation highlights emerging therapeutic options across multiple GI conditions that non-specialist clinicians commonly manage. Limited detail provided as this is a summary of multiple separate studies rather than primary research.

Liver/NASHOther
PubMed14 Apr 2026·Annals of internal medicine● 3/10i

Nephrology: What You May Have Missed in 2025.

Finerenone plus empagliflozin combination data emerged alongside other nephrology findings including AI models for AKI prediction and interventions for patients on dialysis. Annual review article covering multiple 2025 nephrology studies across AKI management, kidney function factors, and dialysis complications. This provides the first mention of dual finerenone-empagliflozin use data, potentially signaling combination therapy development in chronic kidney disease.

KidneySGLT2BayerBoehringer Ingelheim
ClinicalTrials13 Apr 2026·Phase 3● 8/10iHigh impact

A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity

Eli Lilly is conducting a Phase 3 head-to-head trial comparing retatrutide versus tirzepatide in adults with obesity. The double-blind study targets 800 participants over 89 weeks with primary endpoint of percent body weight change, completing December 2026. This represents the first direct comparison between Eli Lilly's next-generation triple receptor agonist retatrutide and its approved dual agonist tirzepatide in obesity. The trial positions Eli Lilly to potentially establish superiority claims for retatrutide ahead of expected regulatory submissions.

GLP-1Weight lossDrug comparisonsEli Lilly
ClinicalTrials13 Apr 2026·Phase 3● 8/10iHigh impact

A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial

Phase 3 trial evaluating retatrutide once weekly in adults with type 2 diabetes who have obesity or overweight, including a subset with obstructive sleep apnea. Enrolling 1,000 participants across 89 weeks with completion expected May 2026, measuring weight reduction and sleep apnea improvement versus placebo. Eli Lilly advances retatrutide into dual indication territory, competing directly with Novo Nordisk's semaglutide and their own tirzepatide in the expanding cardiometabolic space. The inclusion of sleep apnea patients follows Zepbound's December 2024 OSA approval, positioning retatrutide for multiple obesity comorbidities.

GLP-1Weight lossType 2 diabetesEli LillyNovo Nordisk
ClinicalTrials13 Apr 2026·Phase 3● 7/10i

A Phase 3, Randomized, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Phase 3 open-label trial comparing retatrutide with semaglutide in adults with type 2 diabetes inadequately controlled on metformin with or without SGLT2 inhibitor. The study enrolls 1,250 participants over 26 months, targeting HbA1c reduction as the primary endpoint, with completion expected August 2026. Eli Lilly positions retatrutide as a direct competitor to semaglutide in the core type 2 diabetes market, testing their triple-receptor agonist against the current GLP-1 standard. The head-to-head design provides comparative evidence needed for formulary positioning and prescriber confidence.

GLP-1Type 2 diabetesDrug comparisonsEli LillyNovo Nordisk
PubMed13 Apr 2026·Diabetes, obesity & metabolism● 6/10i

Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population-Based Cohort Study.

Semaglutide showed no association with reduced risk of liver cirrhosis (HR 1.3, 95% CI 0.98-1.77) or hepatocellular carcinoma (HR 0.6, 95% CI 0.21-1.51) in adults with type 2 diabetes. Retrospective cohort study of 71,612 patients with median follow-up exceeding 4,000 days. This contradicts emerging hypotheses about GLP-1 receptor agonists providing liver protection beyond metabolic benefits, suggesting hepatic outcomes may not become a differentiated messaging opportunity.

GLP-1Type 2 diabetesLiver/NASHNovo Nordisk
PubMed13 Apr 2026·Diabetes, obesity & metabolism● 6/10i

Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study.

SGLT2 inhibitors reduced hemorrhagic stroke risk by 27% at 5 years (HR 0.73) and ischemic stroke risk by 8% (HR 0.92) in adults with type 2 diabetes and diabetic retinopathy versus DPP-4 inhibitors/metformin. Retrospective cohort study using TriNetX database, 27,556 patients after propensity matching, up to 5 years follow-up. This provides the first stroke prevention data specifically in people with diabetic retinopathy, a high-risk population for cerebrovascular events. The findings come from observational electronic health records rather than randomized controlled trials.

SGLT2Type 2 diabetesCardiovascularReal-world evidence
PubMed13 Apr 2026·Diabetes care● 6/10i

Hepatic Events Prevention by Antihyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-analysis.

GLP-1 receptor agonists showed the lowest risk of hepatic decompensation versus all other diabetes drug classes (HRs 0.16-0.91), while thiazolidinediones had the lowest hepatocellular carcinoma risk and SGLT2 inhibitors the lowest cirrhosis risk. Network meta-analysis of 46 observational studies including 7.1 million adults with type 2 diabetes. This provides the first comprehensive liver safety ranking across all major diabetes drug classes, potentially informing prescribing in patients with existing liver disease risk. All evidence is observational, limiting causal conclusions.

GLP-1SGLT2Type 2 diabetesLiver/NASHDrug comparisonsNovo NordiskEli Lilly
PubMed13 Apr 2026·The lancet. Gastroenterology & hepatology● 6/10i

Global burden of metabolic dysfunction-associated steatotic liver disease, 1990-2023, and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2023.

MASLD prevalence reached 1.3 billion people globally in 2023 (16.1% of population), with cases projected to rise 42% to 1.8 billion by 2050. Global Burden of Disease systematic analysis covering 204 countries from 1990-2023 with forecasting to 2050. This provides the first comprehensive global epidemiological baseline for MASLD, quantifying the massive addressable patient population for emerging therapies like survodutide and semaglutide. High fasting glucose emerged as the largest modifiable risk factor, followed by high BMI.

Liver/NASHGLP-1Boehringer IngelheimNovo Nordisk
PubMed13 Apr 2026·Diabetes, obesity & metabolism● 5/10i

Insulin Sensitive Patients With Impaired Glucose Tolerance: Physiologic and Metabolic Characterization (STOP DIABETES).

One-third of people with impaired glucose tolerance maintain normal insulin sensitivity but develop glucose intolerance through beta cell dysfunction rather than insulin resistance. Post-hoc analysis of STOP DIABETES trial, 329 participants with IGT compared across insulin sensitivity levels. This challenges the dominant insulin resistance paradigm and suggests distinct pathophysiologic subtypes may require different therapeutic approaches. The insulin-sensitive IGT group showed better metabolic profiles but impaired early insulin response compared to insulin-resistant counterparts.

Type 2 diabetesMechanisms
PubMed13 Apr 2026·Diabetes care● 4/10i

Clinical Potential of GIP in Type 2 Diabetes and Obesity.

Tirzepatide's dual GLP-1 and GIP receptor targeting represents the most effective incretin therapy for adults with type 2 diabetes and obesity. Narrative review exploring incretin biology and GIPR mechanisms. This analysis positions GIP receptor activity as a key differentiator driving tirzepatide's superior efficacy, potentially informing next-generation dual agonist development. The relative contribution of GIP versus GLP-1 receptor engagement in tirzepatide's effects remains unestablished.

GLP-1Type 2 diabetesWeight lossEli Lilly
PubMed10 Apr 2026·Clinical hemorheology and microcirculation● 4/10i

A comprehensive review of GLP-1 and aerobic training in cardiovascular disease management.

GLP-1 receptor agonists improve endurance, muscle recovery, fiber type distribution, and energy efficiency while enhancing cardiovascular health through multiple pathways including inflammation reduction and appetite regulation. Comprehensive narrative review examining mechanisms of endogenous and pharmacological GLP-1 effects on cardiovascular and metabolic systems. This provides the first integrated framework connecting GLP-1's exercise-mimetic effects to cardiovascular benefits, potentially supporting new indication expansion beyond diabetes and weight management.

GLP-1CardiovascularMechanisms
PubMed10 Apr 2026·European heart journal. Cardiovascular pharmacotherapy● 4/10i

Implementing SGLT2 Inhibitors in Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Multidisciplinary Expert Perspective.

SGLT2 inhibitors remain significantly underutilized in cardiovascular-kidney-metabolic syndrome despite strong evidence and broad guideline endorsement, according to Italian multidisciplinary expert consensus. Expert opinion based on review of clinical trials, guidelines, and real-world evidence from Italian specialists across diabetology, cardiology, and nephrology. This formalizes what medical affairs teams already know about implementation gaps but provides specialty-specific roadmap for addressing fragmented care and therapeutic inertia. Single-country perspective limits global applicability of proposed solutions.

SGLT2CardiovascularKidneyType 2 diabetes
ClinicalTrials8 Apr 2026·Phase 3● 8/10iHigh impact

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. Once Weekly Versus Tirzepatide 15 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor

Phase 3 head-to-head trial compares CagriSema (dual cagrilintide and semaglutide) 2.4/2.4 mg against tirzepatide 15 mg weekly in adults with type 2 diabetes inadequately controlled on metformin with or without SGLT2 inhibitors. The randomized trial enrolled 1,000 participants with primary endpoints of HbA1c and weight change, completing in March 2026. This represents Novo Nordisk's direct challenge to Eli Lilly's tirzepatide dominance with a novel dual-agonist combination targeting both GLP-1 and amylin receptors. The head-to-head design positions CagriSema for potential differentiation in the competitive dual-agonist space.

GLP-1Type 2 diabetesDrug comparisonsNovo NordiskEli Lilly
ClinicalTrials8 Apr 2026·Phase 3● 8/10iHigh impact

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. Once Weekly Versus Tirzepatide 5 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2 Inhibitor or Both

Phase 3 trial compares CagriSema (cagrilintide + semaglutide combination) 1.0 mg weekly versus tirzepatide 5 mg weekly in 1,023 adults with type 2 diabetes inadequately controlled on metformin, SGLT2 inhibitor, or both. Active comparator design with 68-week duration, completion expected June 2026. This represents Novo Nordisk's direct challenge to Eli Lilly's tirzepatide dominance, testing whether dual amylin/GLP-1 combination can match dual GIP/GLP-1 efficacy in the core type 2 diabetes market. Head-to-head positioning against tirzepatide's lowest approved dose could support differentiated commercial messaging if CagriSema demonstrates superiority.

GLP-1Type 2 diabetesDrug comparisonsNovo NordiskEli Lilly
PubMed7 Apr 2026·Diabetes, obesity & metabolism● 6/10i

Real-World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido-TZP Study.

Tirzepatide reduced HbA1c by 1.07% and body weight by 3.1 kg over 6 months in adults with type 2 diabetes in Japanese real-world practice. Multicenter retrospective observational study of 828 patients treated for 6+ months across 10 centers in Hokkaido. The efficacy remained consistent even in patients switching from existing incretin-based medications, providing first real-world evidence of tirzepatide's effectiveness after GLP-1 failure. Discontinuation rate was 5.4% due to adverse events or other clinical reasons.

GLP-1Type 2 diabetesReal-world evidenceEli LillyNovo Nordisk
ClinicalTrials7 Apr 2026·Phase 3● 6/10i

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes

Phase 3 trial testing RO7795068, a dual GLP-1/GIP receptor agonist, versus placebo for weight management in people with obesity or overweight without type 2 diabetes. The study will enroll 2,000 participants over 72 weeks to assess percent change in body weight. Roche is entering the competitive weight loss market currently dominated by Novo Nordisk's Wegovy and Eli Lilly's Zepbound, targeting people without diabetes who represent the largest obesity population. Completion in July 2028 positions this as a potential third major dual-hormone option if successful.

GLP-1Weight lossHoffmann-La Roche
PubMed5 Apr 2026·Obesity (Silver Spring, Md.)● 7/10i

Weight Loss With GLP-1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta-Analysis.

Tirzepatide provides greater weight loss than semaglutide or liraglutide in adults with obesity without diabetes, with maximum tolerated doses achieving the largest reductions followed by tirzepatide 15mg, 10mg, semaglutide 2.4mg, tirzepatide 5mg, and liraglutide 3mg. Network meta-analysis of 15 RCTs, 14,059 patients. This is the first head-to-head comparison across all three FDA-approved obesity medications in adults without diabetes, establishing tirzepatide's superiority over existing GLP-1 options.

GLP-1Weight lossDrug comparisonsEli LillyNovo Nordisk
ClinicalTrials2 Apr 2026·Phase 3● 7/10i

A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes Mellitus

Boehringer Ingelheim's survodutide (BI 456906) is being tested in a placebo-controlled phase 3 trial for weight loss in adults with overweight or obesity and type 2 diabetes. The 76-week study enrolled 755 participants randomized 2:1 active to placebo, measuring percentage weight loss and achievement of ≥5% weight reduction. This positions Boehringer as a potential third major player in the GLP-1 obesity market, currently dominated by Novo Nordisk's Wegovy and Eli Lilly's Zepbound. The trial completion in December 2025 could establish survodutide as another weekly injectable option for people with diabetes and obesity.

GLP-1Weight lossType 2 diabetesBoehringer Ingelheim
ClinicalTrials2 Apr 2026·Phase 3● 7/10i

A Phase 3, Randomised, Double-blind, Parallel-group, Event-driven, Cardiovascular Safety Study With BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity With Established Cardiovascular Disease (CVD) or Chronic Kidney Disease, and/or at Least Two Weight-related Complications or Risk Factors for CVD

A phase 3 cardiovascular outcomes trial is testing survodutide (BI 456906), a dual GLP-1/glucagon receptor agonist, in 5,533 adults with overweight or obesity and established cardiovascular disease or chronic kidney disease. The randomized, double-blind, placebo-controlled study compares two doses of once-weekly subcutaneous survodutide against placebo over up to 2.25 years. This represents Boehringer Ingelheim's entry into the competitive obesity market with a differentiated dual mechanism approach. The trial aims to demonstrate cardiovascular safety non-inferiority, a regulatory requirement for obesity drugs in high-risk populations.

GLP-1Weight lossCardiovascularBoehringer Ingelheim
PubMed2 Apr 2026·The New England journal of medicine● 6/10i

GLP-1 Receptor Agonists.

GLP-1 receptor agonists reduce cardiovascular risk and slow renal failure progression in high-risk patients with type 2 diabetes through large-scale randomized controlled trials. Review article in NEJM summarizing established mechanisms and clinical benefits. Confirms cardiovascular and kidney benefits already incorporated into current prescribing guidelines and reimbursement decisions. Highlights ongoing concerns about muscle and bone mass loss as potential long-term safety considerations.

GLP-1Type 2 diabetesWeight lossCardiovascularKidneySide effectsNovo NordiskEli Lilly
FDA1 Apr 2026·New Drug Approval (NDA/BLA)● 10/10iHigh impact

FDA Approves Foundayo (Orforglipron) — New Drug Approval (NDA/BLA)

FDA approved orforglipron (Foundayo, Eli Lilly) for type 2 diabetes -- a once-daily oral small-molecule GLP-1 receptor agonist. Orforglipron is the first non-peptide oral GLP-1 approved in the US; oral semaglutide (Rybelsus, Novo Nordisk) has been approved for T2D since 2019 and expanded to obesity in January 2026. Unlike Rybelsus, orforglipron requires no fasting or water volume restrictions before dosing.

GLP-1Type 2 diabetesPricing/accessEli LillyNovo Nordisk
FDA1 Apr 2026·FDA Press Release● 8/10iHigh impact

FDA Approves First New Molecular Entity Under National Priority Voucher Program

FDA approved Foundayo (orforglipron) on April 1, 2026, marking the fifth approval under the Commissioner's National Priority Voucher pilot program. This represents approval of the first small-molecule oral GLP-1 receptor agonist, distinct from the peptide-based oral semaglutide (Rybelsus) approved by FDA in 2019. Eli Lilly gains competitive positioning in the oral GLP-1 space with a differentiated mechanism that requires no fasting restrictions. The approval leverages FDA's expedited voucher pathway designed to incentivize development of treatments addressing unmet medical needs.

GLP-1Type 2 diabetesEli Lilly
PubMed1 Apr 2026·Obesity (Silver Spring, Md.)● 7/10i

Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP-1 Receptor Agonists: A Network Meta-Analysis of Randomized Controlled Trials.

Metabolic/bariatric surgery produces 10.3% greater total weight loss than GLP-1 receptor agonists at under 2 years, with the gap narrowing but persisting at longer follow-up. Network meta-analysis of 30 RCTs, 20,015 patients. This provides the first head-to-head comparison across all available GLP-1 therapies versus surgery, confirming surgery's superiority while positioning tirzepatide as the closest non-surgical alternative. Comparisons were indirect through lifestyle intervention as common comparator.

GLP-1Weight lossEli Lilly
PubMed1 Apr 2026·Obesity (Silver Spring, Md.)● 7/10i

Disparities in Prescription of Long-Acting GLP-1s.

Black and Hispanic patients with obesity were 49% and 47% less likely to receive semaglutide or tirzepatide compared to White patients, disparities that largely disappeared after Massachusetts Medicaid expanded coverage. Retrospective analysis of 2,060 patients at a tertiary care center, January and April 2024. This provides the first evidence that state Medicaid coverage policy directly eliminates racial prescribing disparities for GLP-1 medications. Analysis limited to single health system in Massachusetts.

GLP-1Pricing/accessNovo NordiskEli Lilly
PubMed1 Apr 2026·Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery● 7/10i

Cardiovascular outcomes and mortality of bariatric surgery versus glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis.

Bariatric surgery reduced mortality by 43%, major cardiovascular events by 35%, and heart failure by 55% compared to GLP-1 receptor agonists in adults with obesity. Meta-analysis of 5 observational cohorts, 39,569 patients. This provides the first head-to-head comparison of these major obesity treatments on hard cardiovascular outcomes, showing substantial advantages for surgery. Observational design limits causal inference due to potential confounding and selection bias.

GLP-1CardiovascularWeight lossNovo NordiskEli Lilly
PubMed1 Apr 2026·The lancet. Diabetes & endocrinology● 7/10i

Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study.

GLP-1 receptor agonists combined with comprehensive lifestyle interventions reduced MACE risk by 43% compared to poor lifestyle habits without GLP-1 therapy in adults with type 2 diabetes. Prospective cohort study of 98,261 US veterans over 632,543 person-years of follow-up. This provides the first large-scale evidence quantifying the additive cardiovascular benefit of combining GLP-1 therapy with multiple lifestyle factors beyond diet and exercise alone.

GLP-1CardiovascularType 2 diabetesReal-world evidence
PubMed1 Apr 2026·Obesity reviews : an official journal of the International Association for the Study of Obesity● 7/10i

GLP-1 Receptor Agonists for the Prevention of New-Onset Heart Failure: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials.

GLP-1 receptor agonists reduced new-onset heart failure risk by 23% in patients with type 2 diabetes or obesity without existing heart failure. Meta-analysis of 6 placebo-controlled RCTs, 52,752 participants. This establishes primary prevention of heart failure as a new GLP-1 benefit, extending beyond the known secondary prevention data in patients with established HFpEF. The protective effect was independent of glucose or weight control but correlated with cardiovascular benefits.

GLP-1Cardiovascular
PubMed1 Apr 2026·Heart, lung & circulation● 7/10i

Initiators of Semaglutide in General Practice in New South Wales, 2020-2023: A Retrospective Cohort Study.

Semaglutide initiations in New South Wales increased 82-fold from 448 in 2020 to 36,814 in 2023, with the proportion prescribed for people without type 2 diabetes rising from 8% to 34%. Retrospective cohort analysis of 59,009 patients across 680 general practices, 2020-2023. This provides first real-world evidence of semaglutide's rapid expansion into weight management, confirming the market shift toward non-diabetes indications that Novo Nordisk has actively pursued. The study reveals socioeconomic disparities in access that could influence reimbursement discussions.

GLP-1Weight lossType 2 diabetesPricing/accessReal-world evidenceNovo Nordisk
PubMed1 Apr 2026·Diabetes, obesity & metabolism● 6/10i

Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: A systematic review and meta-analysis.

Liraglutide improved menstrual frequency by 1.76 effect size, reduced BMI, and enhanced insulin sensitivity in women with PCOS and overweight. Meta-analysis of 7 RCTs with 330 patients showed benefits across metabolic and reproductive parameters versus control treatments. This provides first pooled evidence for GLP-1 agonist efficacy in PCOS reproductive outcomes, expanding beyond established metabolic benefits. Small sample size and high heterogeneity for menstrual frequency limit generalizability.

GLP-1Weight lossNovo Nordisk
PubMed1 Apr 2026·Diabetes, obesity & metabolism● 6/10i

A treat-to-target approach for obesity management: A post hoc analysis of the SURMOUNT-5 trial.

About 23-34% of patients with obesity treated with tirzepatide and 14-21% treated with semaglutide reached proposed treat-to-target thresholds for waist-to-height ratio or BMI reduction. Post hoc analysis of SURMOUNT-5 trial, 751 patients, 72 weeks. This provides the first structured target framework for obesity treatment goals, moving beyond simple weight loss percentages to defined metabolic risk thresholds. The analysis was post hoc rather than a prespecified endpoint.

GLP-1Weight lossDrug comparisonsEli LillyNovo Nordisk
PubMed1 Apr 2026·International journal of obesity (2005)● 6/10i

Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison.

Tirzepatide achieved 31.6% weight reduction versus 19.7% for semaglutide and 24.1% for retatrutide in MC4R knockout mice, a model of severe genetic obesity. Preclinical study, 21-day treatment duration in mice deficient in melanocortin pathways. This provides the first head-to-head comparison of major GLP-1 therapies in severe genetic obesity, suggesting these agents work through MC4R-independent mechanisms.

GLP-1Weight lossDrug comparisonsEli LillyNovo Nordisk
PubMed1 Apr 2026·Diabetes, obesity & metabolism● 6/10i

Effects of GLP-1 receptor agonists on cognitive function in patients with type 2 diabetes: A systematic review and meta-analysis based on randomized controlled trials.

GLP-1 receptor agonists improved cognitive function scores by 1.33 points on MMSE and 1.70 points on MoCA versus placebo in adults with type 2 diabetes. Meta-analysis of 18 RCTs, 11,114 patients. This provides first pooled RCT evidence that GLP-1RAs may protect against diabetes-related cognitive decline, potentially expanding their therapeutic positioning beyond glucose control. High heterogeneity (I2 = 82-96%) limits confidence in the effect size.

GLP-1Type 2 diabetesBrain/Neuro
PubMed1 Apr 2026·Diabetes, obesity & metabolism● 6/10i

Impact of conventional lipid-lowering therapy on circulating levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis of randomised controlled trials.

Conventional lipid-lowering drugs increase plasma PCSK9 levels by 23.25 ng/mL across all major drug classes including statins, ezetimibe, and fibrates. Meta-analysis of 14 RCTs with 1,313 participants across multiple treatment arms. This provides the first comprehensive quantification of PCSK9 elevation across all conventional lipid therapies, confirming a mechanistic concern that has lacked systematic evidence. Subgroup analyses show variation by drug intensity and type, but the overall signal is consistent.

PCSK9CardiovascularDrug comparisonsRegeneronSanofiAmgen
PubMed1 Apr 2026·Diabetes, obesity & metabolism● 6/10i

GLP-1 receptor agonists and cardiovascular outcomes in Asian, Black or African American, and White populations: An updated meta-analysis including the SOUL trial.

GLP-1 receptor agonists reduced cardiovascular risk by 27% in Asian populations versus 14% in White populations, with similar but non-significant effects in Black or African American populations. Meta-analysis of 9 trials including 74,703 participants with type 2 diabetes or overweight/obesity. This provides the first robust evidence of differential GLP-1RA cardiovascular benefits across racial groups, with Asian populations showing significantly greater relative risk reduction. The finding emerges from inclusion of the recent SOUL trial data.

GLP-1CardiovascularNovo NordiskEli Lilly
PubMed1 Apr 2026·Clinical obesity● 6/10i

GLP-1 Receptor Agonists Versus Bariatric Surgery: Effects of Weight Loss and BMI on Subsequent General Surgical Procedures.

Bariatric surgery reduces BMI by 9.89 points more than GLP-1 receptor agonists before general surgery procedures, with 13% lower complication odds versus GLP-1RAs. Retrospective cohort study of 9,470 patients from Epic Cosmos database, 2016-2024, with entropy balancing for baseline differences. This provides the first head-to-head comparison of weight loss interventions on surgical outcomes, challenging the assumption that GLP-1RAs offer equivalent perioperative risk reduction. Study lacks a no-intervention control group, limiting conclusions about absolute benefit of either approach.

GLP-1Weight lossReal-world evidence
PubMed1 Apr 2026·Obesity science & practice● 5/10i

Targeting Multiple Gut-Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy.

Gut hormone analogs (GLP-1s like semaglutide, tirzepatide) and naltrexone-bupropion combination target different brain pathways in obesity treatment, creating mechanistic rationale for combination therapy. Narrative review synthesizing existing evidence on gut-brain axis mechanisms. This establishes the scientific foundation for combining GLP-1 receptor agonists with naltrexone-bupropion in patients with inadequate response to monotherapy.

GLP-1Weight lossMechanismsNovo NordiskEli Lilly
PubMed1 Apr 2026·Diabetes, obesity & metabolism● 5/10i

Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis.

Tirzepatide 10-15mg weekly improved patient-reported physical function by 2.26 points on SF-36 and 10.10 points on IWQOL-Lite-CT versus placebo in adults with overweight or obesity. Meta-analysis of 6 RCTs, 4,531 participants, moderate evidence quality. This provides the first systematic evidence that GLP-1/GIP dual agonists enhance physical capacity beyond weight loss, addressing a key quality-of-life endpoint for payer discussions. Extremely high heterogeneity between studies (I2 = 99.8%) limits confidence in the pooled estimates.

GLP-1Weight lossEli Lilly
PubMed1 Apr 2026·Obesity (Silver Spring, Md.)● 5/10i

HDM1002 in Chinese Adults With Overweight/Obesity: A Randomized, Placebo-Controlled, Ascending-Dose Phase 1b Study.

HDM1002, a small-molecule GLP-1 receptor agonist, achieved 6.1 kg weight loss at 200 mg daily versus 1.6 kg with placebo over 28 days in Chinese adults with overweight or obesity. Phase 1b randomized controlled trial, 60 participants across five dose cohorts. This represents the first clinical data for an oral small-molecule GLP-1 agonist showing meaningful weight loss, potentially offering an alternative to injectable peptides in obesity treatment. All participants in higher dose groups experienced adverse events, with two discontinuations.

GLP-1Weight loss
PubMed1 Apr 2026·Diabetes, obesity & metabolism● 5/10i

Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial.

Lixisenatide showed no effect on aortic pulse wave velocity, a cardiovascular risk marker, in adults with type 2 diabetes and chronic kidney disease after 24 weeks versus placebo. Randomized controlled trial of 90 patients, 24 weeks, double-blind design with placebo control. This provides mechanistic insight into why short-acting GLP-1 receptor agonists like lixisenatide showed neutral cardiovascular outcomes in trials while longer-acting agents demonstrated benefits. The study was limited to a single center with modest sample size.

GLP-1CardiovascularKidneyType 2 diabetesSanofiNovo NordiskEli Lilly
PubMed1 Apr 2026·Diabetes, obesity & metabolism● 4/10i

Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double-blind, placebo-controlled trial.

Empagliflozin showed a declining trend in albumin creatinine ratio versus placebo but failed to reach statistical significance at 24 weeks in adults with type 2 diabetes and microalbuminuria. Randomized controlled trial of 79 patients over 24 weeks comparing empagliflozin 10mg daily to placebo. This provides new mechanistic insight into SGLT2 inhibitor kidney protection through suppression of hypoxia-induced angiogenic factors VEGF and ANGPTL2, offering biological explanation for established renal benefits. The primary endpoint missed statistical significance despite early positive trends.

SGLT2Type 2 diabetesKidneyBoehringer IngelheimEli Lilly
PubMed1 Apr 2026·International journal of obesity (2005)● 4/10i

Characterization of jejunal enteroids in human obesity; a model for studying GLP-1 cells.

Jejunal enteroids from adults with severe obesity and type 2 diabetes show reduced GLP-1 secretion in response to high glucose compared to enteroids from adults with severe obesity alone or with prediabetes. Laboratory study using tissue from 34 patients undergoing gastric bypass surgery. This provides the first controlled human model to study GLP-1 cell dysfunction in type 2 diabetes, potentially explaining reduced incretin response in metabolic disease. The model enables drug testing for enteroid-targeted therapies without relying on rare primary tissue samples.

GLP-1Type 2 diabetesWeight lossMechanisms
PubMed1 Apr 2026·Diabetes, obesity & metabolism● 4/10i

The depletion of serine beta-lactamase-like protein (LACTB) ameliorates metabolic dysfunction-associated steatotic liver disease by reducing ubiquitin-mediated degradation of carnitine palmitoyltransferase 2.

LACTB protein levels were elevated in liver tissues from patients with MASLD and high-fat diet mice, with LACTB depletion improving hepatic steatosis, insulin resistance, and inflammation. Preclinical study using patient samples and mouse models with in vitro validation. This identifies a novel therapeutic target mechanism for MASLD through CPT2-mediated fatty acid oxidation, providing new pathway understanding for a disease affecting over 25% of the global population. Early-stage target discovery without established drug development programs.

Liver/NASHMechanisms
PubMed1 Apr 2026·International journal of obesity (2005)● 4/10i

Canagliflozin regulates adipocyte lipolysis in vitro via a SGLT2 independent signaling pathway.

Canagliflozin inhibited adipocyte lipolysis by 35-65% through SGLT2-independent mechanisms involving PI3K/AKT pathway activation and reduced cAMP production. In vitro study using rat primary adipocytes and human SGBS cells with dose-response and mechanistic analyses. This reveals a novel metabolic mechanism for SGLT2 inhibitors beyond glucose control, potentially explaining lipid benefits observed in cardiovascular outcomes trials.

SGLT2MechanismsJohnson & Johnson
PubMed1 Apr 2026·Diabetes, obesity & metabolism● 4/10i

Efsubaglutide Alfa attenuates metabolic dysfunction-associated steatohepatitis in mice with improvements in second harmonic generation-derived fibrosis features.

Efsubaglutide Alfa, a novel long-acting GLP-1 receptor agonist, reduced liver fat accumulation and improved specialized fibrosis measurements in a mouse MASH model over 42 days. Preclinical study in male mice comparing Efsubaglutide Alfa to semaglutide and obeticholic acid. This provides the first direct comparison of this experimental GLP-1RA against semaglutide in MASH, positioning it as a potential competitor in the emerging liver indication space. The study used advanced imaging techniques that detected fibrosis improvements missed by standard histology methods.

GLP-1Liver/NASH
PubMed1 Apr 2026·Obesity reviews : an official journal of the International Association for the Study of Obesity● 3/10i

Comparative Efficacy of Different Exercise Interventions on Intrahepatic Lipid Content, Glucose Homeostasis, and Liver Function in Adults With and Without Nonalcoholic Fatty Liver Disease: A Systematic Review With Pairwise and Network Meta-Analyses.

High-intensity interval training reduced intrahepatic lipid content most effectively (p-score 0.95), followed by aerobic training (0.77), combined training (0.52), and resistance training (0.10) in adults with and without NAFLD. Network meta-analysis of 38 studies with 1,880 participants comparing exercise interventions. This provides the first head-to-head comparison ranking different exercise modalities for liver fat reduction, filling a critical evidence gap for clinical guidelines and treatment algorithms. Exercise also reduced fasting glucose, insulin, HbA1c, and liver enzymes ALT/AST compared to no exercise.

Liver/NASH
PubMed1 Apr 2026·Obesity reviews : an official journal of the International Association for the Study of Obesity● 2/10i

How Bioethics and Reproductive Justice Ought to Inform Glucagon-Like Peptide-1 Receptor Agonists, Research, and Pregnancy.

Bioethics researchers argue that pregnant people are systematically excluded from GLP-1 receptor agonist studies, creating evidence gaps that prevent understanding of safety and efficacy during pregnancy. Theoretical framework analysis applying reproductive justice principles to GLP-1RA research methodology. This highlights a regulatory and commercial challenge facing all GLP-1RA manufacturers as pregnancy safety data remains limited across the drug class.

GLP-1
PubMed31 Mar 2026·European heart journal● 6/10i

Fat, muscle, and anti-obesity medications in cardiovascular disease prevention.

GLP-1 receptor agonists cause substantial lean muscle mass loss alongside fat reduction, potentially undermining long-term cardiovascular benefits through sarcopenia and reduced metabolic resilience. Narrative review synthesizing emerging evidence on muscle preservation strategies. This reframes obesity treatment from total weight loss to body composition optimization, challenging current endpoints and positioning muscle-preserving agents as combination partners. Resistance training remains the primary recommended strategy, while myostatin inhibitors and selective androgen receptor modulators show promise.

GLP-1Weight lossCardiovascular
PubMed31 Mar 2026·Journal of the American College of Cardiology● 6/10i

Obesity and Heart Failure With Reduced Ejection Fraction: A Review.

Most patients with heart failure with reduced ejection fraction have overweight or obesity, but weight loss interventions remain unexplored in this population despite proven safety and efficacy in heart failure with preserved ejection fraction. This JACC review synthesizes existing evidence across multiple studies. The analysis reveals a critical research gap as no novel obesity pharmacotherapies are currently being evaluated specifically in patients with HFrEF, despite mechanistic rationale suggesting potential benefit.

GLP-1Weight lossCardiovascularNovo NordiskEli Lilly
ClinicalTrials30 Mar 2026·Phase 3● 8/10iHigh impact

Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity

Phase 3 trial testing CagriSema (cagrilintide + semaglutide 2.4mg combination) versus placebo, cagrilintide alone, and semaglutide alone in 3,400 people with overweight or obesity. The 1.5-year main study plus 2-year extension tracks weight loss and maintenance after stopping treatment. Novo Nordisk is advancing its dual-hormone combination therapy against established GLP-1 monotherapy to potentially expand its obesity franchise beyond Wegovy. The extension phase design addresses a key clinical question about weight regain after discontinuation that could influence prescriber confidence and payer coverage decisions.

GLP-1Weight lossNovo Nordisk
PubMed30 Mar 2026·BMJ open diabetes research & care● 6/10i

Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH.

Switching from dulaglutide to tirzepatide provided superior HbA1c reduction (greater in high baseline HbA1c, low BMI) and weight loss (greater in non-Hispanic populations) across all patient subgroups at 40 weeks. Phase IV RCT, open-label, active-controlled, adults with type 2 diabetes on stable dulaglutide for 6+ months. This is the first head-to-head switching study between GLP-1 agents, establishing tirzepatide's superiority over Novo's dulaglutide across diverse patient populations.

GLP-1Type 2 diabetesDrug comparisonsEli LillyNovo Nordisk
PubMed28 Mar 2026·JAMA cardiology● 8/10iHigh impact

Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.

Tirzepatide reduced a 6-component cardiorenal composite endpoint by 16% versus dulaglutide (23.7% vs 27.4%, HR 0.84) in people with type 2 diabetes and cardiovascular disease. Post hoc analysis of SURPASS-CVOT double-blind RCT, 13,165 patients, median 46.9 months follow-up. This provides the first head-to-head cardiorenal comparison between tirzepatide and a GLP-1 agonist in high-risk cardiovascular patients, extending beyond the primary non-inferiority finding. Gastrointestinal adverse events were higher with tirzepatide (42.5% vs 35.9%).

GLP-1CardiovascularKidneyType 2 diabetesDrug comparisonsEli LillyNovo Nordisk
ClinicalTrials24 Mar 2026·Phase 3● 7/10i

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)

Phase 3 master protocol evaluates once-daily orforglipron for hypertension treatment in people with obesity or overweight across two independent studies. The placebo-controlled framework targets 974 participants with completion expected September 2027. Eli Lilly is expanding orforglipron beyond its approved type 2 diabetes indication, testing the first small-molecule oral GLP-1 in cardiovascular indication territory dominated by Novo Nordisk's Wegovy. This represents a direct challenge to semaglutide's expanding label into cardiometabolic conditions.

GLP-1CardiovascularWeight lossEli Lilly
PubMed23 Mar 2026·Diabetes, obesity & metabolism● 8/10iHigh impact

GLP-1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta-Analysis of RCTs.

Tirzepatide achieved 7.17-fold greater likelihood of ≥5% weight loss versus placebo in adults with type 2 diabetes, outperforming subcutaneous semaglutide (4.74-fold) and oral semaglutide (2.85-fold). Network meta-analysis of 127 RCTs, 58,976 participants across seven GLP-1 receptor agonists. This provides the first comprehensive head-to-head comparison showing tirzepatide's superior weight loss efficacy across both diabetes and non-diabetes populations. Higher nausea and vomiting rates occurred with tirzepatide versus semaglutide formulations.

GLP-1Weight lossType 2 diabetesDrug comparisonsEli LillyNovo Nordisk
PubMed23 Mar 2026·Cell metabolism● 3/10i

The many pathways driving liver inflammation in MASH.

Multiple parallel inflammatory pathways drive MASH development, fueled by hepatic lipotoxicity, intestinal dysbiosis, and pro-inflammatory diets affecting immune responses. Cell Metabolism review of mechanistic pathways and therapeutic approaches. This mechanistic framework explains why most MASH drugs require pleiotropic metabolic and anti-inflammatory properties rather than single-target approaches.

Liver/NASHMechanisms
PubMed21 Mar 2026·Lancet (London, England)● 8/10iHigh impact

Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.

Orforglipron 12 mg and 36 mg achieved superior HbA1c reduction versus oral semaglutide 7 mg and 14 mg, with treatment differences ranging from -0.24% to -0.68%. Phase 3 RCT with 1,698 adults with type 2 diabetes inadequately controlled on metformin, 52-week duration, head-to-head comparison. This provides the first head-to-head data showing an oral non-peptide GLP-1 receptor agonist outperforming oral semaglutide in glycemic control. Higher gastrointestinal side effects and discontinuation rates with orforglipron (9-10% vs 4-5%) may limit uptake despite superior efficacy.

GLP-1Type 2 diabetesDrug comparisonsEli LillyNovo Nordisk
ClinicalTrials20 Mar 2026·Phase 3● 7/10i

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Orforglipron is being tested in women with stress urinary incontinence who have obesity or overweight in two phase 3 studies under a master protocol. The trials will enroll 1,000 participants with 58-week follow-up, comparing daily oral orforglipron to placebo. This represents a novel indication expansion for Eli Lilly's small-molecule GLP-1 beyond diabetes and weight management, targeting a large underserved population where weight loss could provide therapeutic benefit. This marks the first major GLP-1 trial in urological conditions, potentially opening a new market segment.

GLP-1OtherEli Lilly
ClinicalTrials20 Mar 2026·Phase 3● 6/10i

A Phase 3 Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Trial

Phase 3 trial evaluating orforglipron once daily in people with obesity or overweight and osteoarthritis of the knee. The study targets 800 participants over 74 weeks in a placebo-controlled design, measuring pain reduction via the WOMAC Pain Subscale. This represents Eli Lilly's push to expand orforglipron beyond type 2 diabetes into new indications where GLP-1s show promise. The trial combines weight loss with joint pain relief, targeting a large patient population not directly addressed by current obesity medications.

GLP-1Weight lossEli Lilly
ClinicalTrials19 Mar 2026·Phase 3● 9/10iHigh impact

Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)

Phase 3 SURMOUNT-1 tests once-weekly tirzepatide at three doses versus placebo in adults without type 2 diabetes who have obesity or are overweight with comorbidities. The randomized, double-blind trial targets 2,539 participants with primary efficacy assessment at 72 weeks. This represents tirzepatide's pivotal obesity trial against placebo, potentially supporting Eli Lilly's bid to compete directly with Wegovy in the non-diabetic obesity market. A prediabetes subgroup continues long-term to assess diabetes prevention.

Weight lossGLP-1Eli Lilly
FDA19 Mar 2026·Supplemental Approval — Efficacy● 6/10i

FDA Approves Wegovy (Semaglutide) — Supplemental Approval — Efficacy

FDA approved a supplemental efficacy application for Wegovy (semaglutide, Novo Nordisk) on March 19, 2026. This represents a label expansion for the already-approved obesity drug, adding new efficacy data or indication refinements to the existing NDA. Novo Nordisk continues to strengthen Wegovy's competitive position in the obesity market against Eli Lilly's Zepbound through additional clinical evidence.

GLP-1Weight lossNovo NordiskEli Lilly
FDA19 Mar 2026·Supplemental Approval — Efficacy [Priority Review]● 6/10i

FDA Approves Imcivree (Setmelanotide) — Supplemental Approval — Efficacy [Priority Review]

FDA approved a supplemental application for Imcivree (setmelanotide, Rhythm) on March 19, 2026, under priority review. This represents an efficacy-based label expansion for the melanocortin-4 receptor agonist, which was initially approved for rare genetic obesity disorders. Rhythm gains additional indication breadth in the specialized rare obesity market, where treatment options remain extremely limited. The priority review designation signals FDA recognition of significant unmet medical need in the expanded patient population.

Weight lossOtherRhythm
FDA19 Mar 2026·FDA Press Release● 6/10i

FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide

FDA approved a higher dose of Wegovy (semaglutide 7.2 mg) for weight loss and long-term weight maintenance in adults on March 19, 2026. This represents a label expansion for the existing obesity indication, building on Wegovy's current 2.4 mg weekly injection. Novo Nordisk gains a potential differentiation tool in the competitive obesity market, where Eli Lilly's Zepbound already offers dual-mechanism action. The approval marks the fourth product under FDA's National Priority Voucher Program.

GLP-1Weight lossNovo Nordisk
ClinicalTrials13 Mar 2026·Phase 3● 5/10i

A Phase 3, Randomized, Active- and Placebo-Controlled, Partially-Blinded Study to Compare the Efficacy and Safety of KAI-9531 Administered Once Weekly Versus Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

A phase 3 trial is testing KAI-9531, a once-weekly subcutaneous injection, versus semaglutide and placebo for weight loss in 1,200 people with obesity without diabetes. The 76-week randomized, partially-blinded study targets completion in March 2028 with percent body weight change as the primary endpoint. Kailera is positioning KAI-9531 as a direct competitor to Wegovy in the crowded obesity market, attempting to differentiate through superior weight loss efficacy. This represents another entrant challenging Novo Nordisk's established position in obesity treatment.

GLP-1Weight lossKaileraNovo Nordisk
ClinicalTrials12 Mar 2026·Phase 3● 8/10iHigh impact

The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease

Phase 3 cardiovascular outcomes trial evaluating CagriSema (cagrilintide + semaglutide 2.4 mg/2.4 mg) versus placebo in people with established cardiovascular disease. 7,101 participants enrolled with up to 4.5 years follow-up, measuring time to first 3-point MACE (cardiovascular death, non-fatal MI, non-fatal stroke). Novo Nordisk is testing whether their dual amylin/GLP-1 combination can deliver cardiovascular benefits beyond current GLP-1 monotherapy in high-risk populations. This represents the first major cardiovascular outcomes trial for a dual incretin/amylin combination therapy.

GLP-1CardiovascularWeight lossNovo Nordisk
ClinicalTrials12 Mar 2026·Phase 3● 7/10i

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 8)

Phase 3 trial (AMAZE 8) comparing Novo Nordisk's investigational NNC0487-0111 to semaglutide for weight loss in adults with overweight or obesity and type 2 diabetes. Targeting 1,000 participants with expected completion in December 2028, this head-to-head comparison uses body weight change as the primary endpoint. Novo Nordisk is testing a potential next-generation GLP-1 against its own approved semaglutide, suggesting confidence in superior weight loss efficacy. This positions NNC0487-0111 as a potential successor to Wegovy in the competitive obesity market.

GLP-1Weight lossType 2 diabetesDrug comparisonsNovo Nordisk
ClinicalTrials11 Mar 2026·Phase 3● 6/10i

Long-term Effects of Semaglutide on Diabetic Retinopathy in Subjects With Type 2 Diabetes

Phase 3 randomized controlled trial evaluating semaglutide versus placebo for diabetic retinopathy progression in adults with type 2 diabetes. The 5-year study targets 1,500 participants and measures 3-step Early Treatment Diabetic Retinopathy Study progression as primary endpoint. Novo Nordisk is testing whether their established GLP-1 can expand beyond diabetes and weight management into ophthalmology, potentially opening a new indication where no GLP-1 currently holds approval. This represents one of the longest-duration ophthalmology studies in the metabolic space.

GLP-1Type 2 diabetesNovo Nordisk
ClinicalTrials3 Mar 2026·Phase 3● 7/10i

A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Retatrutide Treatment in the Maintenance of Weight Reduction in Individuals With Obesity

Phase 3b trial evaluates retatrutide's ability to maintain weight loss in people with obesity through an 80-week open-label lead-in followed by 36-week randomized withdrawal to placebo or continued treatment. The study enrolls 643 participants with completion expected in April 2028, testing two retatrutide doses against placebo switch. This addresses a critical commercial question for Eli Lilly: whether people can maintain weight loss after achieving it, a key payer concern for obesity drugs. The withdrawal design mirrors successful maintenance studies that supported Wegovy's market access positioning.

Weight lossGLP-1Eli Lilly
ClinicalTrials27 Feb 2026·Phase 3● 5/10i

A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Study Comparing the Efficacy and Safety of HRS9531 Injection Versus Semaglutide Injection in Subjects With Obesity

HRS9531, a weekly injectable from Chinese sponsor Fujian Shengdi, is being tested head-to-head against semaglutide in 572 adults with obesity. This 52-week, open-label phase 3 trial completed enrollment and measures percentage weight change as the primary endpoint. The study represents another Chinese GLP-1 biosimilar or follow-on entering direct competition with Novo Nordisk's established semaglutide franchise in obesity. This adds to multiple Chinese developers pursuing GLP-1 programs, potentially targeting domestic and emerging markets where branded pricing creates access gaps.

GLP-1Weight lossDrug comparisonsFujian Shengdi Pharmaceutical Co., Ltd.Novo Nordisk
ClinicalTrials25 Feb 2026·Phase 3● 6/10i

A Placebo-controlled Comparability Study to Compare Two Presentations of CagriSema in Participants With Overweight or Obesity

Phase 3 trial compares two presentation formats of CagriSema (cagrilintide plus semaglutide) delivered via different injection devices for weight loss in adults with overweight or obesity. The placebo-controlled study plans to enroll 1,400 participants with completion expected in late 2027. This device comparability study reflects Novo Nordisk's preparation for potential CagriSema approval, ensuring multiple delivery options for their dual hormone approach. The timing suggests Novo is advancing toward late-stage regulatory preparations for their next-generation weight management therapy.

GLP-1Weight lossNovo Nordisk
ClinicalTrials17 Feb 2026·Phase 3● 8/10iHigh impact

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants With Type 1 Diabetes and Obesity or Overweight

Phase 3 trial evaluating tirzepatide once weekly versus placebo in 905 adults with type 1 diabetes and obesity or overweight, measuring HbA1c change as primary endpoint. Double-blind, placebo-controlled study expected to complete November 2026, currently active but not recruiting. Eli Lilly is testing tirzepatide in type 1 diabetes, a population where GLP-1 agonists have limited evidence and where weight management remains an unmet need alongside glycemic control. This represents expansion into a new diabetes indication where insulin remains the cornerstone therapy.

GLP-1Type 1 diabetesWeight lossEli Lilly
ClinicalTrials12 Jan 2026·Phase 3● 8/10iHigh impact

A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity

Phase 3 cardiovascular outcomes trial testing tirzepatide versus placebo in 15,374 adults with obesity, measuring time to first major adverse cardiovascular event (death, MI, stroke, coronary revascularization, or heart failure). The randomized, double-blind, placebo-controlled study completed enrollment with expected results in October 2027. This represents Eli Lilly's bid to establish tirzepatide's cardiovascular benefits in obesity, directly competing with Novo Nordisk's Wegovy which gained MACE indication approval in March 2024. The massive enrollment suggests Lilly is positioning for a broad obesity cardiovascular claim to differentiate from Novo's narrower obesity plus established CVD indication.

GLP-1Weight lossCardiovascularEli LillyNovo Nordisk
PubMed1 Jan 2026·BMJ medicine● 4/10i

Metabolic dysfunction associated steatotic liver disease: mechanisms, diagnosis, and management in adults.

MASLD affects the most people globally with chronic liver disease and drives both liver and cardiometabolic complications. Narrative review summarizing current pathogenesis understanding, non-invasive diagnostics, and international management guidelines. This provides the first comprehensive framework since the reclassification from NAFLD to MASLD, shifting focus toward systemic metabolic dysfunction as the central driver. The review lacks novel data but establishes the new diagnostic and treatment paradigm for the renamed condition.

Liver/NASHType 2 diabetes
PubMed1 Jan 2026·Diabetes, metabolic syndrome and obesity : targets and therapy● 3/10i

Correlation Between the Thyroid Hormone Levels and Type 2 Diabetes Mellitus in Non-Alcoholic Fatty Liver Disease.

The FT3/FT4 ratio shows moderate discriminatory performance for type 2 diabetes in patients with NAFLD, with those in the highest quartile having 73% lower odds of diabetes (OR 0.27). Retrospective analysis of 4,942 hospitalized patients with NAFLD at one Chinese center, 2020-2023. This provides the first evidence that thyroid hormone ratios could serve as metabolic risk markers in NAFLD populations, potentially offering a novel biomarker approach. Single-center Chinese data may limit generalizability to other populations.

Type 2 diabetesLiver/NASH
ClinicalTrials12 Dec 2025·Phase 3● 8/10iHigh impact

Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c. (CagriSema s.c.) Once Weekly for Weight Management and Long-term Weight Maintenance in Participants With Obesity

Novo Nordisk is testing CagriSema (cagrilintide plus semaglutide combination) against placebo in 609 people with obesity across a 3-year phase 3 trial for weight management and long-term maintenance. The study includes a main phase followed by an extension where all participants receive active treatment at different doses. This represents Novo's dual-hormone strategy to extend beyond single GLP-1 therapy, competing directly with Eli Lilly's tirzepatide franchise in obesity. The 3-year duration targets the critical question of sustained weight loss that regulators and payers prioritize.

Weight lossGLP-1Novo NordiskEli Lilly
ClinicalTrials5 Nov 2025·Phase 3● 8/10iHigh impact

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)

ATTAIN-1 is testing orforglipron, Eli Lilly's oral small-molecule GLP-1 receptor agonist, versus placebo in 3,127 adults with obesity or overweight with weight-related comorbidities. This 72-week phase 3 trial with 2-year extension for people with prediabetes is placebo-controlled and has completed enrollment. Eli Lilly is building the clinical foundation for orforglipron in obesity, following its April 2026 FDA approval for type 2 diabetes where it differentiated from Novo Nordisk's oral semaglutide with no dosing restrictions. This represents Eli Lilly's entry into oral GLP-1 obesity treatment, directly challenging Novo Nordisk's pending high-dose oral semaglutide for obesity approved in January 2026.

GLP-1Weight lossEli LillyNovo Nordisk
ClinicalTrials29 Sept 2025·Phase 3● 6/10i

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obstructive Sleep Apnea and Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial

Eli Lilly is testing orforglipron, its oral small-molecule GLP-1, in adults with moderate-to-severe obstructive sleep apnea and obesity or overweight across two parallel studies. The phase 3 master protocol will enroll 600 participants through November 2026, comparing orforglipron to placebo with sleep apnea severity as the primary endpoint. This represents Eli Lilly's move into sleep medicine with orforglipron, targeting an indication where Zepbound recently gained FDA approval in December 2024. The dual-study design separates participants by PAP therapy use, suggesting potential for differentiated positioning across OSA treatment patterns.

GLP-1Weight lossOtherEli Lilly
ClinicalTrials17 Sept 2025·Phase 3● 3/10i

A Phase 3, Multi-center, Open-label, Randomized Study to Evaluate the Efficacy and Safety of JY09 Versus Dulaglutide in Patients With T2DM Inadequately Controlled by Metformin

Phase 3 open-label trial comparing two doses of JY09 versus dulaglutide as add-on therapy to metformin in adults with type 2 diabetes. Enrolled 600 participants with HbA1c as primary endpoint, expected completion October 2026. Beijing Dongfang Biotech is testing a GLP-1 candidate in a crowded T2D market dominated by established players like Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide). This represents another Chinese biotech attempting to challenge Western incumbents in the lucrative diabetes space.

GLP-1Type 2 diabetesDrug comparisonsBeijing Dongfang Biotech Co., Ltd.
ClinicalTrials5 Sept 2025·Phase 3● 4/10i

A Study of HS-20094 Versus Dulaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabete

Phase 3 trial tests HS-20094, a once-weekly GLP-1 receptor agonist, versus dulaglutide in 546 adults with type 2 diabetes inadequately controlled on metformin alone or with SGLT2 inhibitors. Open-label comparison running 52 weeks with HbA1c reduction as primary endpoint, completion expected March 2027. Jiangsu Hansoh enters the competitive once-weekly GLP-1 space dominated by Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, targeting the large metformin-failure population. Direct head-to-head with dulaglutide positions this Chinese biosimilar for potential market share in Asia-Pacific regions.

GLP-1Type 2 diabetesDrug comparisonsJiangsu Hansoh Pharmaceutical
ClinicalTrials24 Aug 2025·Phase 3● 5/10i

A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Patients With Type 2 Diabetes

RAY1225, a GLP-1 receptor agonist from Guangdong Raynovent Biotech, is being tested head-to-head against semaglutide as add-on therapy to oral antidiabetic drugs in adults with type 2 diabetes. The open-label phase 3 trial targets 600 participants with expected completion in December 2026, measuring HbA1c reduction as the primary endpoint. This represents another Chinese biotech company attempting to challenge Novo Nordisk's semaglutide dominance in the established GLP-1 diabetes market. The direct comparator design suggests confidence in differentiation, though the open-label format may limit regulatory acceptance versus blinded superiority trials.

GLP-1Type 2 diabetesDrug comparisonsGuangdong Raynovent BiotechNovo Nordisk
ClinicalTrials23 Jul 2025·Phase 3● 8/10iHigh impact

A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease

Phase 3 randomized, double-blind, placebo-controlled study evaluates retatrutide once weekly in people with severe obesity and established cardiovascular disease. The trial targets 1,800 participants over 113 weeks, with primary endpoint of percent change in body weight from baseline. Eli Lilly is advancing retatrutide, a triple agonist (GLP-1/GIP/glucagon), into a high-risk cardiovascular population that represents a significant commercial opportunity beyond standard obesity treatment. This positions retatrutide as a potential competitor to Wegovy, which gained cardiovascular risk reduction approval in March 2024 for people with obesity and established CVD.

Weight lossCardiovascularGLP-1Eli Lilly
ClinicalTrials12 Jun 2025·Phase 3● 5/10i

A Phase III,Multicenter,Randomized,Open-label,Parallel-controlled Study Comparing the Efficacy and Safety of HRS9531 With Semaglutide in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Metformin Monotherapy or in Combination With SGLT2 Inhibitors

HRS9531, a once-weekly GLP-1 agonist from Fujian Shengdi Pharmaceutical, is being tested head-to-head against semaglutide in adults with type 2 diabetes inadequately controlled on metformin with or without SGLT2 inhibitors. The phase 3 randomized open-label trial enrolled 884 people with 52-week follow-up, measuring HbA1c change as the primary endpoint. This represents another Chinese biosimilar challenge to Novo Nordisk's semaglutide franchise, following similar efforts from BrightGene and Raynovent in the competitive GLP-1 space. The trial completed enrollment and is expected to read out by September 2026.

GLP-1Type 2 diabetesDrug comparisonsFujian Shengdi PharmaceuticalNovo Nordisk
ClinicalTrials18 Apr 2025·Phase 3● 8/10iHigh impact

A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)

TRIUMPH-1 is a Phase 3 master protocol testing retatrutide (Eli Lilly's triple agonist) in 2,300 people with obesity or overweight without type 2 diabetes, including subsets with knee osteoarthritis and obstructive sleep apnea. The 89-week double-blind, placebo-controlled trial with optional 24-week extension measures weight change, osteoarthritis pain scores, and sleep apnea severity. Eli Lilly is positioning retatrutide across multiple obesity-related conditions beyond weight management, directly competing with Novo Nordisk's Wegovy in the obesity market. This comprehensive approach targets three distinct indications within one protocol, reflecting Lilly's strategy to establish retatrutide as a multi-indication obesity therapy.

Weight lossCardiovascularEli LillyNovo Nordisk
ClinicalTrials7 Feb 2025·Phase 3● 5/10i

A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of BGM0504 Versus Semaglutide Once Weekly As Add-on Therapy to Metformin And/or Sulfonylureas in Patients with Type 2 Diabetes

BGM0504, a once-weekly injection from BrightGene Bio-Medical, is being tested against semaglutide as add-on therapy to metformin and/or sulfonylureas in adults with type 2 diabetes. The open-label phase 3 trial enrolls 537 participants in China with expected completion in March 2026. This represents a direct challenge to Novo Nordisk's Ozempic franchise in the Chinese market from a domestic biosimilar competitor. The head-to-head design against branded semaglutide signals BrightGene's confidence in demonstrating non-inferiority for regulatory approval and market access positioning.

GLP-1Type 2 diabetesDrug comparisonsBrightGene Bio-Medical Technology Co., Ltd.Novo Nordisk
ClinicalTrials19 Aug 2024·Phase 3● 5/10i

A 26-Week,Randomised,Open-Label,Multicenter,Active-Controlled,Parallel-Design,Phase III Clinical Trial to Compare the Efficacy and Safety of Insulin Degludec/Liraglutide Injection With XULTOPHY® Once Daily Via Subcutaneous Injection in Chinese Subjects With Type 2 Diabetes

Phase 3 trial compares Chinese-manufactured insulin degludec/liraglutide combination to Novo Nordisk's Xultophy in adults with type 2 diabetes. Open-label study targets 510 participants over 26 weeks with HbA1c reduction as primary endpoint, expected completion October 2025. Tonghua Dongbao tests its biosimilar combination against the established Novo Nordisk product in the Chinese market. This represents China's push toward domestic alternatives in the GLP-1/insulin combination space.

GLP-1Type 2 diabetesDrug comparisonsTonghua Dongbao Pharmaceutical Co.,LtdNovo Nordisk

Weekly briefing

Key signals, decoded for pharma executives and investors. Free, every week.

Try for freeWant to know more? Book a consultation →